The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 2004 Oct;18(10):1565-8
Date
09/29/2004Pubmed ID
15452588DOI
10.1038/sj.leu.2403482Scopus ID
2-s2.0-6244309270 (requires institutional sign-in at Scopus site) 20 CitationsAbstract
Patients with high-risk acute myelogenous leukemia (AML) in first remission are at increased risk for disease recurrence and are often considered for allogeneic bone marrow transplantation (BMT) if there is a suitable HLA-identical sibling donor. Analysis of results from randomized clinical trials comparing different treatment strategies for patients with AML (chemotherapy, autologous BMT, and allogeneic BMT) suggests that allogeneic BMT may be a superior treatment modality for patients in the high-risk subgroup. Interpretation of clinical trial results, however, is problematic due to poor compliance with transplant options, absence of studies specifically designed to addresses this question, and ongoing redefinition of the high-risk subgroup. Alternative allogeneic transplant approaches to reduce toxicity from graft-versus-host disease and enhance graft-versus-leukemia reactivity may offer therapeutic promise in this patient population.
Author List
Drobyski WRAuthor
William R. Drobyski MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Bone Marrow TransplantationClinical Trials as Topic
Graft vs Host Disease
Humans
Leukemia, Myeloid, Acute
Risk Factors
Transplantation, Homologous
